OLE Study to Evaluate Safety / Efficacy of ZD4522

Phase 3CompletedNCT00654303

AstraZeneca3,500 enrolled

Overview

The purpose of this study is to assess the long term safety of Crestor.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

3,500

Conditions

Hypercholesterolaemia

Interventions

RosuvastatinDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Completion of previous Crestor study as listed in the protocol. Exclusion Criteria: * Pregnant or breast feeding women, or not using appropriate contraception. * Abnormal lab values as listed in the protocol.

Outcomes

Primary Outcomes

Safety, as determined by adverse events, laboratory data, physical examination and ECG.

Time frame: 12 weekly

Secondary Outcomes

Success in achieving goals for Cholesterol levels

Time frame: 12 weekly

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.